Patrick Y. Wen
温佩翠
MD
Director, Center for Neuro-Oncology神经肿瘤中心主任
👥Biography 个人简介
Patrick Wen leads the Center for Neuro-Oncology at Dana-Farber and is a world authority on GBM clinical trials. He co-led the AVAGLIO trial establishing bevacizumab in GBM and is a key figure in developing response assessment criteria for brain tumors.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Bevacizumab in GBM
Co-led the AVAGLIO phase III trial evaluating bevacizumab plus temozolomide/radiotherapy, establishing its role in newly diagnosed GBM.
Response Assessment
Co-developed the RANO criteria for standardized response assessment in neuro-oncology trials, adopted globally.
Clinical Trial Infrastructure
Built Dana-Farber's neuro-oncology trial program into one of the most productive in the USA, enrolling patients on dozens of first-in-human studies.
Representative Works 代表性著作
Bevacizumab plus radiotherapy–temozolomide for newly diagnosed glioblastoma (AVAGLIO)
New England Journal of Medicine (2013)
Phase III trial showing bevacizumab improved PFS but not OS in newly diagnosed GBM; set international standard.
Updated response assessment criteria for high-grade gliomas: RANO criteria
Journal of Clinical Oncology (2010)
Established RANO criteria that replaced MacDonald criteria, improving consistency in GBM response evaluation.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Timothy Cloughesy
UCLA Health / David Geffen School of Medicine
Michael Weller
University Hospital Zurich / University of Zurich
Susan M. Chang
University of California San Francisco (UCSF)
Roger Stupp
Northwestern University Feinberg School of Medicine
关注 温佩翠 的研究动态
Follow Patrick Y. Wen's research updates
留下邮箱，当我们发布与 Patrick Y. Wen（Dana-Farber Cancer Institute / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment